Since immune checkpoint therapies such as CTLA-4 (4) and PD-1 (5) have developed rapidly in AML in recent years, tumor microenvironment (TME) is an important cellular environment for immune cells, stromal cells, and extracellular matrix molecules and has attracted more and more attention (6, 7). Here, CTLA4 is linked to acute myeloid leukemia.